

Content available at: <https://www.ipinnovative.com/open-access-journals>

IP Indian Journal of Neurosciences

Journal homepage: <https://www.ijonline.org/>

Case Report

Therapeutic efficacy of rivastigmine in Alzheimer's disease

Durga Prasad S^{1*}, Tirath Patel²¹Dept. of Pharmacology, American University of Antigua College of Medicine, Antigua, Antigua and Barbuda²American University of Antigua College of Medicine, Antigua, Antigua and Barbuda

ARTICLE INFO

Article history:

Received 09-12-2023

Accepted 27-12-2023

Available online 30-12-2023

Keywords:

Mild Cognitive Impairment

Alzheimer's disease

Mini-Mental State Examination (MMSE)

Rivastigmine

memantine

ABSTRACT

A 72-year-old White male complained of memory loss, trouble recalling names and events, and a regular-duty deterioration. Hypertension, type 2 diabetes, and hyperlipidemia characterized the patient's history. He never drank alcohol or used illicit drugs. His mother had Alzheimer's, and his father had a stroke. The patient's physical examination was unremarkable except for a 20- out-of-30 Mini-Mental State Examination (MMSE) score, suggesting mild cognitive impairment. Rivastigmine 1.5 mg twice a day was started, with an eight-week escalation to 6 mg twice daily. He was given rivastigmine and memantine to slow cognitive impairment. Treatment efficacy and side effects were extensively examined. This report highlights the therapeutic efficacy of rivastigmine in improving cognitive function in patients with Alzheimer's disease. The improvement in cognitive function and absence of significant adverse effects suggest that the treatment approach was effective in managing the patient's Alzheimer's disease.

This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License](#), which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

1. Introduction

Rivastigmine, classified as a cholinesterase inhibitor, has received approval for its use in addressing mild to moderate cases of Alzheimer's disease. A neurodegenerative disorder, it is primarily marked by deteriorating cognitive abilities, manifesting as memory impairment, challenges in language skills, and reduced spatial awareness.¹ The prevailing therapeutic strategies for Alzheimer's encompass the use of cholinesterase inhibitors like rivastigmine, alongside N-methyl-D-aspartate (NMDA) receptor antagonists, including drugs like memantine.

Rivastigmine's mechanism of action involves the inhibition of acetylcholinesterase, an enzyme responsible for the degradation of acetylcholine, a crucial neurotransmitter for cognitive processes. By blocking this enzyme, rivastigmine increases acetylcholine

concentrations in the brain, potentially enhancing cognitive abilities in individuals suffering from Alzheimer's disease.² Evidence of rivastigmine's efficacy in boosting cognitive capabilities in Alzheimer's patients has been established through various clinical studies, including randomized, double-blind, placebo-controlled trials.

In a comprehensive study involving 609 individuals with mild to moderate Alzheimer's disease, conducted in a randomized, double-blind, and placebo-controlled manner, it was observed that rivastigmine significantly enhanced cognitive abilities and the performance of daily activities compared to a placebo.³ Furthermore, a similar study encompassing 725 patients also suffering from mild to moderate Alzheimer's demonstrated that rivastigmine notably boosted both cognitive and overall functioning when contrasted with a placebo.⁴

Besides its application in Alzheimer's disease, research on rivastigmine has extended to include various other cognitive decline-related conditions, such as dementia in

* Corresponding author.

E-mail address: durgs360@gmail.com (Durga Prasad S).

Parkinson's disease and Lewy body dementia. Dementia related to Parkinson's disease is an advancing disorder marked by deteriorating cognitive abilities. This includes issues with memory, language processing, and spatial orientation, alongside Parkinson's characteristic motor symptoms. On the other hand, Lewy body dementia, another neurodegenerative condition, is distinguished by cognitive decline, visual hallucinations, and motor symptoms like those seen in Parkinson's disease. In both these conditions, studies have indicated that rivastigmine can enhance cognitive functions.⁵

The effectiveness of rivastigmine in treating Alzheimer's disease and other similar disorders holds substantial significance in clinical contexts. Conditions like Alzheimer's and related neurodegenerative diseases are linked with considerable health complications and mortality rates, necessitating effective therapies to enhance the life quality of those affected.⁶ Rivastigmine stands out as a hopeful option for ameliorating cognitive abilities in individuals suffering from Alzheimer's and other disorders marked by cognitive decline. It is crucial to conduct further investigations to comprehend rivastigmine's long-term impacts and to assess its applicability in other neurodegenerative diseases.

2. Case Presentation

2.1. Patient information

A Caucasian male, aged 72, came in with primary concerns of losing memory, struggling to recall names and events, and a noticeable decrease in his ability to carry out daily tasks over the previous year. His medical background includes conditions like hypertension, type 2 diabetes, and high cholesterol levels. There was no evidence of alcohol or illegal substance use in his history. A look into his family medical history shows his mother suffered from Alzheimer's disease, while his father had experienced a hemorrhagic stroke. During the physical examination, he appeared generally normal, but his Mini-Mental State Examination (MMSE) score was 20 out of a possible 30, pointing to a moderate level of cognitive impairment.

2.2. Diagnostic assessment

The individual underwent a comprehensive series of cognitive evaluations, including the MMSE, Clinical Dementia Rating (CDR), and the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog). These assessments indicated a moderate level of cognitive impairment, leading to a tentative diagnosis of Alzheimer's disease.

2.3. Treatment

The patient began a regimen of rivastigmine, starting at 1.5 mg twice a day, with plans to incrementally increase the dose to 6 mg twice daily over a period of eight weeks. Additionally, memantine was prescribed to manage and potentially slow down the progression of cognitive decline. Throughout the treatment process, the patient's response and any adverse reactions were meticulously monitored to gauge the effectiveness of the therapy.

3. Result

After an eight-week regimen of rivastigmine, there was a marked enhancement in the patient's cognitive abilities, as evidenced by the increase in his MMSE score from 20 to 24 out of a possible 30. This improvement reflects significant progress in his cognitive functioning. Additionally, his ADAS-Cog score witnessed a considerable reduction, falling from 23 to 15, further substantiating the cognitive gains achieved. The patient noted a noticeable decrease in his memory loss issues and a substantial improvement in conducting his everyday activities, indicating an enhancement in his overall quality of life.

3.1. Follow up

Throughout the course of treatment, the patient did not experience any major adverse effects, suggesting a good tolerance to the medication. This aspect is particularly encouraging, as it highlights the safety and patient compatibility of the treatment regimen. The patient's therapy, comprising a continued dosage of 6 mg of rivastigmine taken twice daily along with memantine, was maintained under stringent observation. This was done to closely monitor his cognitive state and promptly identify any potential adverse reactions or necessary adjustments in his treatment plan.

4. Discussion

The consistent improvement in the patient's cognitive tests and self-reported abilities underscore the effectiveness of rivastigmine in managing symptoms of cognitive decline. The positive outcome in this case also supports the potential for this treatment strategy to be beneficial for similar cases, warranting further exploration and validation in broader clinical settings. Alzheimer's disease represents a continually advancing neurodegenerative condition, impacting crucial cognitive functions such as memory, language, and spatial understanding. Present therapeutic strategies for Alzheimer's disease encompass the use of cholinesterase inhibitors and antagonists of the N-methyl-D-aspartate (NMDA) receptor, like memantine. Specifically, rivastigmine, a cholinesterase inhibitor, is sanctioned for use in mild to moderate cases of Alzheimer's disease.⁷

The action mechanism of rivastigmine involves the suppression of acetylcholine breakdown by inhibiting acetylcholinesterase, an enzyme critical in cognitive functions. This inhibition leads to raised acetylcholine levels in the brain, potentially enhancing cognitive abilities in Alzheimer's patients. The effectiveness of rivastigmine in improving cognitive performance in Alzheimer's has been validated, as exemplified in this case study.⁸

Moreover, rivastigmine's efficacy extends to other cognitive decline-related conditions like Parkinson's disease dementia and Lewy body dementia. Its positive impact on cognitive functions in these conditions is likely attributed to the similarities in their pathophysiology with Alzheimer's disease.^{9,10}

5. Conclusions

The case involving a 72-year-old Caucasian male diagnosed with probable Alzheimer's underscores the criticality of prompt diagnosis and management in curbing cognitive deterioration in Alzheimer's. Employing validated cognitive assessments and evidence-backed treatment modalities, such as rivastigmine, is vital for enhancing treatment outcomes. Gradual dose adjustment and vigilant monitoring for adverse reactions and treatment efficacy are key to maximizing therapeutic benefits. In summary, this case report accentuates the role of rivastigmine in bettering cognitive capabilities in Alzheimer's patients. The observed cognitive improvement and the absence of notable adverse effects imply the effectiveness of the treatment strategy in managing the patient's condition.

6. Source of Funding

None.

7. Conflict of Interest

None.

References

1. Nguyen K, Hoffman H, Chakkamparambil B, Grossberg GT. Evaluation of rivastigmine in Alzheimer's disease. *Neurodegener Dis Manag.* 2021;11(1):35–48.
2. Kurz A, Farlow M, Quarg P, Spiegel R. Disease stage in Alzheimer disease and treatment effects of rivastigmine. *Alzheimer Dis Assoc Disord.* 2004;18(3):123–8.
3. Ismail MF, Elmesad AN, Salem NAH. Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer's disease. *Int J Nanomedicine.* 2013;8:393–406. doi:10.2147/IJN.S39232.
4. Gabelli C. Rivastigmine: an update on therapeutic efficacy in Alzheimer's disease and other conditions. *Curr Med Res Opin.* 2003;19(2):69–82. doi:10.1185/0300799039117029.
5. Farlow MR, Small GW, Quarg P, Krause A. Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis. *Dement Geriatr Cogn Disord.* 2005;20(2-3):192–7.
6. Emre M, Cummings JL, Lane RM. Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences. *J Alzheimers Dis.* 2007;11(4):509–19.
7. Santo SD, Prinelli F, Adorni F, Caltagirone C, Musicco M. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease. *J Alzheimers Dis.* 2013;35(2):349–61.
8. Auriacombe S, Pere JJ, Loria-Kanza Y, Vellas B. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. *Curr Med Res Opin.* 2002;18(3):129–38.
9. Adler G, Brassen S, Chwalek K, Dieter B, Teufel M. Prediction of treatment response to rivastigmine in Alzheimer's dementia. *J Neurol Neurosurg Psychiatry.* 2004;75(2):292–4.
10. Winblad B, Cummings J, Andreasen N, Grossberg G, Onofri M, Sadowsky C, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease—rivastigmine patch versus capsule. *Int J Geriatr Psychiatry.* 2007;22(5):456–67.

Author biography

Durga Prasad S, Professor  <https://orcid.org/0009-0003-4496-4688>

Tirath Patel, Student

Cite this article: Durga Prasad S, Patel T. Therapeutic efficacy of rivastigmine in Alzheimer's disease. *IP Indian J Neurosci* 2023;9(4):237–239.